Yuri Tolkach1, Heidrun Gevensleben1, Ralph Bundschuh2, Aydan Koyun1, Daniela Huber3, Christina Kehrer3, Thomas Hecking3, Mignon-Denise Keyver-Paik3, Christina Kaiser3, Hojjat Ahmadzadehfar2, Markus Essler2, Walther Kuhn3, Glen Kristiansen4. 1. Institute of Pathology, Center for Integrated Oncology, University Hospital Bonn, University of Bonn, Sigmund-Freud-Str. 25, 53127, Bonn, Germany. 2. Department of Nuclear Medicine, Center for Integrated Oncology, University Hospital Bonn, University of Bonn, 53127, Bonn, Germany. 3. Department of Obstetrics and Gynecology, Center for Integrated Oncology, University Hospital Bonn, University of Bonn, 53127, Bonn, Germany. 4. Institute of Pathology, Center for Integrated Oncology, University Hospital Bonn, University of Bonn, Sigmund-Freud-Str. 25, 53127, Bonn, Germany. glen.kristiansen@ukbonn.de.
Abstract
PURPOSE: Prostate-specific membrane antigen (PSMA), a protein product of the folate hydrolase 1 (FOLH1) gene, is gaining increasing acceptance as a target for positron emission tomography/computer tomography (PET/CT) imaging in patients with several cancer types, including breast cancer. So far, PSMA expression in breast cancer endothelia has not been sufficiently characterized. METHODS: This study comprised 315 cases of invasive carcinoma of no special type (NST) and lobular breast cancer (median follow-up time 9.0 years). PSMA expression on tumor endothelia was detected by immunohistochemistry. Further, vascular mRNA expression of the FOLH1 gene (PSMA) was investigated in a cohort of patients with invasive breast cancer provided by The Cancer Genome Atlas (TCGA). RESULTS: Sixty percent of breast cancer cases exhibited PSMA-positive endothelia with higher expression rates in tumors of higher grade, NST subtype with Her2-positivity, and lack of hormone receptors. These findings were confirmed on mRNA expression levels. The highest PSMA rates were observed in triple-negative carcinomas (4.5 × higher than in other tumors). Further, a case of a patient with metastatic breast cancer showing PSMA expression in PET/CT imaging and undergoing PSMA radionuclide therapy is discussed in detail. CONCLUSIONS: This study provides a rationale for the further development of PSMA-targeted imaging in breast cancer, especially in triple-negative tumors.
PURPOSE:Prostate-specific membrane antigen (PSMA), a protein product of the folate hydrolase 1 (FOLH1) gene, is gaining increasing acceptance as a target for positron emission tomography/computer tomography (PET/CT) imaging in patients with several cancer types, including breast cancer. So far, PSMA expression in breast cancer endothelia has not been sufficiently characterized. METHODS: This study comprised 315 cases of invasive carcinoma of no special type (NST) and lobular breast cancer (median follow-up time 9.0 years). PSMA expression on tumor endothelia was detected by immunohistochemistry. Further, vascular mRNA expression of the FOLH1 gene (PSMA) was investigated in a cohort of patients with invasive breast cancer provided by The Cancer Genome Atlas (TCGA). RESULTS: Sixty percent of breast cancer cases exhibited PSMA-positive endothelia with higher expression rates in tumors of higher grade, NST subtype with Her2-positivity, and lack of hormone receptors. These findings were confirmed on mRNA expression levels. The highest PSMA rates were observed in triple-negative carcinomas (4.5 × higher than in other tumors). Further, a case of a patient with metastatic breast cancer showing PSMA expression in PET/CT imaging and undergoing PSMAradionuclide therapy is discussed in detail. CONCLUSIONS: This study provides a rationale for the further development of PSMA-targeted imaging in breast cancer, especially in triple-negative tumors.
Entities:
Keywords:
Breast cancer; Endothelium; Expression; FOLH1; Marker; PET/CT; PSMA
Authors: James J Vornov; Diane Peters; Mike Nedelcovych; Kristen Hollinger; Rana Rais; Barbara S Slusher Journal: Neurochem Res Date: 2019-11-20 Impact factor: 3.996
Authors: Valentí Gómez; Myria Galazi; Gregory Weitsman; James Monypenny; Fahad Al-Salemee; Paul R Barber; Kenrick Ng; Richard Beatson; Bálint Szokol; László Orfi; Greg Mullen; Bart Vanhaesebroeck; Simon Chowdhury; Hing Y Leung; Tony Ng Journal: Mol Cancer Ther Date: 2022-04-01 Impact factor: 6.261
Authors: Amanda Kristiansson; Anders Örbom; Jonas Ahlstedt; Helena Karlsson; Wahed Zedan; Magnus Gram; Bo Åkerström; Sven-Erik Strand; Mohamed Altai; Joanna Strand; Oskar Vilhelmsson Timmermand Journal: Biomolecules Date: 2021-02-10
Authors: Agnieszka Morgenroth; Ebru Tinkir; Andreas T J Vogg; Ramya Ambur Sankaranarayanan; Fatima Baazaoui; Felix M Mottaghy Journal: Breast Cancer Res Date: 2019-10-22 Impact factor: 6.466
Authors: Hojjat Ahmadzadehfar; Kambiz Rahbar; Richard P Baum; Robert Seifert; Katharina Kessel; Martin Bögemann; Harshad R Kulkarni; Jingjing Zhang; Carolin Gerke; Rolf Fimmers; Clemens Kratochwil; Hendrik Rathke; Harun Ilhan; Johanna Maffey-Steffan; Mike Sathekge; Levent Kabasakal; Francisco Osvaldo Garcia-Perez; Kalevi Kairemo; Masha Maharaj; Diana Paez; Irene Virgolini Journal: Eur J Nucl Med Mol Imaging Date: 2020-05-08 Impact factor: 9.236
Authors: M J M Uijen; Y H W Derks; W A M van Gemert; J Nagarajah; R I J Merkx; M G M Schilham; J Roosen; B M Privé; S A M van Lith; C M L van Herpen; M Gotthardt; S Heskamp Journal: Eur J Nucl Med Mol Imaging Date: 2021-06-12 Impact factor: 9.236